#United States #New York #Levi & Korsinsky #Securities Class Action #Regeneron Pharmaceuticals

Overview

Levi & Korsinsky, LLP has recently issued an alert to investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) regarding a pending securities class action. This action covers a class period extending from August 1, 2025, through May 15, 2026. Investors are encouraged to verify their eligibility to recoup any losses sustained during this period.

Background of the Case

The allegations primarily focus on statements made by Regeneron about the Phase III Fianlimab-Libtayo Study. Allegations include claims that Regeneron minimized significant risks surrounding the study’s clinical differentiation just prior to a key trial readout. The firm overseeing the case is urging those affected by the fallout from this situation to come forward and seek lead plaintiff appointment—set for September 14, 2026.

On April 28, 2026, REGN shares were valued at $731.77; however, following the disclosures on May 15, 2026, the shares plummeted to $629.68, revealing a loss of over 13.95% after the disclosures of the trial results.

Allegations Concerning Fianlimab-Libtayo

The lawsuit emphasizes how management's statements regarding clinical trial outcomes might have misled investors. Specifically, there were assertions that the prolonged event accrual slowdown in the study was consistent with favorable outcomes, which allegedly downplayed the risk of inadequate differentiation between their active treatment and standard therapies.

The class action contends that Regeneron failed to adequately inform investors of delays that were affecting the study’s statistical significance. Furthermore, critical last-minute changes in the protocol aimed at altering the patient selection criteria—increasing the pool for progression-free survival analysis—were allegedly not disclosed adequately to shareholders before the abrupt stock decline.

Why This Matters to Investors

The Fianlimab-Libtayo trial was marketed as a potentially groundbreaking therapeutic option for advanced melanoma. Investors had relied on Regeneron's optimistic projections about its potential efficacy compared to established treatments like pembrolizumab. When news about the protocol changes and the failure to meet primary endpoints surfaced, investor confidence took a significant hit, causing a stark reaction in the stock market.

Legal Considerations

As detailed in the lawsuit, the claims against Regeneron span issues of material misrepresentation during the class period. The firm alleges that statements made about the clinical trial were misleading, compromising investor information regarding the real risks involved. Investors have been reassured that even those who sold their shares during the timeframe in question may still qualify to recover losses.

Levi & Korsinsky is recognized in the field of shareholder litigation, being listed among the top 50 firms for seven consecutive years according to ISS Securities Class Action Services. The firm has successfully recovered substantial losses for investors in previous class action cases.

Frequently Asked Questions

What are the key misstatements in the lawsuit? The complaint indicates that Regeneron downplayed risks concerning its clinical differentiation that impacted share performance during critical trial phases.

What is the timeline for the case? The class action encompasses events between August 1, 2025, and May 15, 2026, with crucial disclosures impacting the share price on April 29 and May 15.

Where is the case filed? The action is submitted to the United States District Court for the Southern District of New York.

Conclusion

Investors who experienced losses during the noted class period are suggested to act swiftly and seek guidance from experienced attorneys at Levi & Korsinsky. Those concerned about the repercussions on their investments may contact the firm for a confidential initial assessment at no cost. It is essential for affected investors to understand the importance of this class action and how they might navigate the claims process effectively.

For more insights, investors can reach Levi & Korsinsky at (212) 363-7500 or via email at [email protected].